Therefore, we propose that β-glucogallin would inhibit free glucose binding at the active site of AKR1B1, preventing sorbitol production under hyperglycemic conditions such as in patients suffering from diabetic eye disease. The gene discussed is AKR1B1; the disease is diabetic eye disease.